drugset / Trial / NCT02570542
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2
Active not recruiting
59 enrolled
Memorial Sloan Kettering Cancer Center
Columbia University · collabEndeavor Health · collabMedical College of Wisconsin · collabSanofi · collabUniversity Hospitals Seidman Cancer Center · collabUniversity of Nebraska · collabUniversity of Rochester · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to study the impact of stem cell dose on outcome after autologous transplant.
Timeline
- Start
- 2015-10
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Cytarabine | Small molecule | 100 mg/m2 | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |
| Background | Melphalan | Small molecule | 140 mg/m2 | — |
| Background | Plerixafor | Small molecule | — | — |
| Background | carmustine | Small molecule | 300 mg/m2 | — |